Finance

Lists
IMCR:NASDAQ
Immunocore Holdings PLC - ADR
28,34 $
+1,87%
(+0,52) 1D
28,34 $
0,00% (0,00)
After hours
Closed: 14 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMCR...
Open
27,60 $
High
28,45 $
Low
27,50 $
Mkt. cap
1,48 մլրդ
Avg. vol.
429,45 հզր
Volume
0,00
52-wk high
40,71 $
52-wk low
27,50 $
EPS
-0,37 $
Beta
0,81
Shares outstanding
51,50 մլն
No. of employees
524
Open
27,60 $
High
28,45 $
Low
27,50 $
Mkt. cap
1,48 մլրդ
Avg. vol.
429,45 հզր
Volume
0,00
52-wk high
40,71 $
52-wk low
27,50 $
EPS
-0,37 $
Beta
0,81
Shares outstanding
51,50 մլն
No. of employees
524
News stories
From web sources and news partners
Profile
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
About Immunocore Holdings PLC - ADR
CEOBahija Jallal
Employees524
Founded2008
Headquarters-
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to IMCR in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMCR in the last 3 months.
Highest
Current 28,34 $
100,00 $ (+252,86%)
Average
62,83 $ (+121,70%)
Lowest
35,00 $ (+23,50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
100,00 $
+252,9%
09/21/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
50,00 $
+76,4%
08/21/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
43,00 $
+51,7%
08/07/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
74,00 $
+161,1%
08/06/2026
Graig Suvannavejh
Mizuho Securities
Hold
Maintained
35,00 $
+23,5%
08/07/2026
Gil Blum
Needham
Buy
Maintained
75,00 $
+164,6%
08/06/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
05/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
60,00 $
+111,7%
05/06/2026
Jeff Jones
Oppenheimer
Buy
Maintained
86,00 $
+203,5%
04/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
60,00 $
+111,7%
04/14/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
33,00 $
+16,4%
03/15/2026
Last report
06 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,02 $ / 0,02 $
-195,65%miss
Revenue / Est. (USD)
115,93 մլն / 110,92 մլն
+4,51%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
103,69 մլն
104,48 մլն
106,68 մլն
115,93 մլն
Cost of goods sold
71,08 մլն
81,52 մլն
434,00 հզր
75,03 մլն
Cost of revenue
71,08 մլն
81,52 մլն
434,00 հզր
75,03 մլն
Research and development expenses
-
-
61,11 մլն
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39,78 մլն
42,64 մլն
37,85 մլն
43,89 մլն
Operating expense
39,78 մլն
22,92 մլն
98,96 մլն
43,89 մլն
Total operating expenses
110,86 մլն
104,44 մլն
99,40 մլն
118,92 մլն
Operating income
-7,17 մլն
37,00 հզր
7,28 մլն
-3,00 մլն
Other non operating income
5,06 մլն
-15,22 մլն
-
-
EBT including unusual items
304,00 հզր
-15,79 մլն
13,27 մլն
-514,00 հզր
EBT excluding unusual items
304,00 հզր
-15,79 մլն
11,50 մլն
-3,58 մլն
Income tax expense
481,00 հզր
14,27 մլն
301,00 հզր
294,00 հզր
Effective tax rate
158,22%
-90,33%
2,27%
-57,20%
Other operating expenses
-
-19,73 մլն
-
-
Net income
-177,00 հզր
-30,06 մլն
12,97 մլն
-808,00 հզր
Net profit margin
-0,17%
-28,77%
12,16%
-0,70%
Earnings per share
-
-0,60
0,25
-0,02
Interest and investment income
4,12 մլն
3,91 մլն
3,42 մլն
3,58 մլն
Interest expense
-3,04 մլն
-3,05 մլն
-3,05 մլն
-3,06 մլն
Net interest expenses
1,08 մլն
853,00 հզր
367,00 հզր
520,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-6,37 մլն
871,00 հզր
8,23 մլն
-1,97 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps